Astellas v. Lupin: Consent Judgment Upholds Mirabegron Patent Portfolio in Landmark Pharma Case

In a significant resolution for pharmaceutical patent litigation, Astellas Pharma, Inc. secured a consent judgment against Lupin Limited (operating through its Zydus entities) in the U.S. District Court for the District of Delaware, confirming the validity and enforceability of four patents protecting Myrbetriq® (mirabegron extended-release tablets). Filed on July 28, 2023, and closed on February 19, 2026, after 937 days of litigation, this case underscores the enduring strength of branded pharmaceutical companies’ patent portfolios in defending against ANDA-based generic entry.

The outcome — a consent judgment admitting infringement and barring Zydus from commercializing its generic mirabegron products until patent expiration — carries direct implications for overactive bladder (OAB) drug patent litigation strategy, ANDA filer risk assessment, and the broader Paragraph IV certification landscape. For patent attorneys, in-house IP counsel, and R&D teams operating in the specialty pharmaceutical space, this case offers concrete lessons on portfolio defense, HATCH-Waxman litigation tactics, and market exclusivity protection.

Case Overview

The Parties

Patents at Issue

This landmark case involved four U.S. patents protecting Myrbetriq® (mirabegron extended-release tablets). These patents cover the extended-release delivery mechanism and therapeutic application of mirabegron, representing layered patent protection typical of brand pharmaceutical lifecycle management strategies.

• • US 11,707,451 B2 — Lead patent, covering formulation and/or method-of-use claims
• • US X,XXX,780 — Covering formulation, composition, and/or method-of-use claims
• • US X,XXX,409 — Covering formulation, composition, and/or method-of-use claims
• • US X,XXX,189 — Covering formulation, composition, and/or method-of-use claims

The Verdict & Legal Analysis

Outcome

The Consent Judgment, entered by the Delaware District Court, concluded the litigation with the following definitive outcomes:

1. Validity Confirmed: Zydus admitted that the ‘780, ‘451, ‘409, and ‘189 patents are valid and enforceable for purposes of this action and in connection with ANDA No. 209488.
2. Infringement Admitted: Zydus admitted that at least one claim of each of the four patents is infringed by the Zydus ANDA Products.
3. Injunctive Relief Granted: Zydus is barred from making, using, selling, offering for sale, importing, or distributing the accused generic mirabegron products in the United States until the expiration of all four patents, including any patent term extensions (PTE), patent term adjustments (PTA), pediatric exclusivity, or other regulatory exclusivities.
4. Dismissal of Claims: Complaints across all four related civil actions were dismissed without prejudice and without costs or attorneys’ fees to either party.
5. Retained Jurisdiction: The court retained jurisdiction to enforce compliance with the consent judgment and related agreements.

No monetary damages were disclosed in the consent judgment.

Verdict Cause Analysis

The infringement action arose under the Hatch-Waxman Act, where Zydus’s filing of ANDA No. 209488 with Paragraph IV certifications constituted a technical act of infringement under 35 U.S.C. § 271(e)(2). The consent judgment’s admission of infringement across all four patents — without any carve-out for invalidity or non-infringement — signals either the strength of Astellas’s claim construction position or a negotiated entry date arrangement embedded in related settlement agreements (not publicly disclosed).

The multi-patent, multi-case structure of Astellas’s enforcement strategy reflects a deliberate layered portfolio approach: by asserting overlapping formulation, composition, and method-of-use patents simultaneously across multiple ANDA proceedings, Astellas created compounding litigation risk for Zydus, increasing the settlement incentive.

Legal Significance

This consent judgment reinforces several important principles in pharmaceutical patent litigation:

• • Portfolio layering works: Asserting multiple patents with staggered expiration dates increases the burden on generic challengers and complicates invalidity strategies.
• • Consent judgments as enforcement tools: While not a contested ruling, the court’s retention of jurisdiction transforms this consent judgment into an enforceable order — any premature market entry by Zydus triggers contempt or injunctive proceedings.
• • Paragraph IV litigation risk: The full admission of validity and infringement, without disclosed carve-outs, may reflect a negotiated delayed-entry arrangement — a common but confidential component of Hatch-Waxman settlements.

Strategic Takeaways

For Patent Holders: Pursue multi-patent, multi-case enforcement strategies in Hatch-Waxman litigation. Layered portfolios covering formulation, method of use, and composition create compounding invalidity burdens that often incentivize early settlement.

For Generic Filers (ANDA Applicants): Thorough pre-filing freedom-to-operate analysis across the entire branded patent portfolio — not just the Orange Book-listed patents — is essential. Unanticipated blocking patents can force consent judgments that delay market entry.

For R&D Teams: Extended-release formulation patents can provide significant exclusivity extensions beyond base compound patents. Designing around delivery mechanism patents requires early-stage IP risk mapping.